Comparison of the Toxicities and Efficacies of the Combination Chemotherapy Regimens in Advanced Gastric Cancer Patients Who Achieved Complete Response after Chemotherapy.
10.4166/kjg.2011.58.6.311
- Author:
Yun Jeung KIM
1
;
Pyung Gohn GOH
;
Eui Sik KIM
;
Su Youn LEE
;
Hee Seok MOON
;
Eaum Seok LEE
;
Jae Kyu SUNG
;
Seok Hyun KIM
;
Byung Seok LEE
;
Hyun Yong JEONG
Author Information
1. Department of Internal Medicine, Chungnam National University, School of Medicine, Daejeon, Korea. Jeonghy@cnuh.co.kr
- Publication Type:Original Article ; Comparative Study ; English Abstract
- Keywords:
Stomach cancer;
Combination therapy;
Treatment outcome;
Drug toxicity
- MeSH:
Adult;
Aged;
Antineoplastic Agents/*therapeutic use/toxicity;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use/toxicity;
Camptothecin/analogs & derivatives/therapeutic use/toxicity;
Cisplatin/therapeutic use/toxicity;
Drug Therapy, Combination;
Female;
Fluorouracil/therapeutic use/toxicity;
Humans;
Leucovorin/therapeutic use/toxicity;
Leukopenia/etiology;
Male;
Middle Aged;
Mucositis/etiology;
Nausea/etiology;
Neoplasm Staging;
Organoplatinum Compounds/therapeutic use/toxicity;
Retrospective Studies;
Stomach Neoplasms/*drug therapy/mortality;
Survival Rate;
Taxoids/therapeutic use/toxicity;
Tomography, X-Ray Computed;
Vomiting/etiology
- From:The Korean Journal of Gastroenterology
2011;58(6):311-317
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: We retrospectively analyzed comparative toxicities and efficacies of chemotherapy regimens in advanced gastric cancer (AGC) patients who achieved complete response (CR) after chemotherapy. METHODS: We reviewed the medical records of 1,203 patients, who were pathologically diagnosed as AGC in a single center between January 2001 and October 2007. On the basis of the Response Evaluation Criteria in Solid Tumors, CR was evaluated with abdominal computed tomography. Toxicities were evaluated using the National Cancer Institute's common toxicity criteria before each chemotherapy cycle. RESULTS: Among the 1,203 AGC patients enrolled in this study, 568 received chemotherapy and 635 received best supportive care. The major chemotherapy regimens were 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX), docetaxel, cisplatin and 5-fluorouracil (DCF) and 5-fluorouracil, leucovorin and irinotecan (FOLFIRI). Among the 568 patients, 51 (9.0%) achieved CR (49 [8.6%] with FOLFOX [n=12], DCF [n=26], or FOLFIRI [n=11] and 2 [0.3%] with etoposide, leucovorin and 5-fluorouracil). For patients administered FOLFOX, DCF, and FOLFIRI, the median time to disease progression was 4 months (range, 1.8-59.5), 15 months (range, 2.9-31.2) and 10 months (range, 2.0-39.5), and the median survival times were 48 months (range, 5.9-74.0), 37 months (range, 14.0-86.0), and 30 months (range, 6.0-50.0), respectively. Grades 3-4 mucositis occurred mostly in patients administered DCF (n=8, 30.8%). Grades 3-4 leucopenia were observed in 1 (8.3%), 11 (42.3%), and 4 (36.4%) patients administered FOLFOX, DCF and FOLFIRI, respectively. No statistically significant differences were observed in the 3 regimens. CONCLUSIONS: All 3 regimens (FOLFOX, DCF and FOLFIRI) were active and tolerable. Their efficacies and toxicities were not significantly different.
